Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Pelz, Joerg O W ^a   Chua, Terence C ^b   Esquivel, Jesus ^c   Stojadinovic, Alexander ^d   Doerfer, Joerg ^a   Morris, David L ^b   Maeder, Uwe ^a   Germer, Christoph Thomas ^a   Kerscher, Alexander G ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b ST GEORGE HOSPITAL   (Australia)

^c ST AGNES HOSPITAL   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERITONEAL SURFACE DISEASE SEVERITY SCORE; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; CARCINOMA; COLORECTAL TUMOR; COMPARATIVE STUDY; EVALUATION; GERMANY; HEALTH SURVEY; HOSPITALIZATION; KAPLAN MEIER METHOD; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PERITONEUM TUMOR; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GERMANY; HEALTH STATUS INDICATORS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650336758     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-689     Document Type: Article

References (19)

1. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000, 88:358-63. 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O, 10640968.
2. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000, 18:3101-3107.
3. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989, 63:364-7. 10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V, 2910444.
4. Koppe MJ, Boerman OC, Oyen WJG, et al. Peritoneal Carcinomatosis of Colorectal Origin: Incidence and Current Treatment Strategies. Annals of Surgery 2006, 243:212-222. 10.1097/01.sla.0000197702.46394.16, 1448921, 16432354.
5. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New England Journal of Medicine 2004, 350:2343-51. 10.1056/NEJMoa032709, 15175436.
6. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:2006-12. 10.1200/JCO.2007.14.9898, 18421053.
7. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. Journal of Clinical Oncology 2005, 23:4866-75. 10.1200/JCO.2005.07.113, 15939922.
8. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. Journal of Clinical Oncology 2007, 25:1670-6. 10.1200/JCO.2006.09.0928, 17470860.
9. Golfinopoulos V, Salanti G, Pavlidis N, et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncology 2007, 8:898-911. 10.1016/S1470-2045(07)70281-4, 17888735.
10. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology 2008, 26:2013-9. 10.1200/JCO.2007.14.9930, 18421054.
11. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. Journal of Clinical Oncology 2004, 22:3284-92. 10.1200/JCO.2004.10.012, 15310771.
12. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. Journal of Clinical Oncology 2009, 27:681-5. 10.1200/JCO.2008.19.7160, 19103728.
13. Pelz JO, Stojadinovic A, Nissan A, et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. Journal of Surgical Oncology 2009, 99:9-15. 10.1002/jso.21169, 18937291.
14. Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. Journal of Clinical Oncology 2006, 24:4011-9. 10.1200/JCO.2006.07.1142, 16921055.
15. Esquivel J, Elias D, Baratti D, et al. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. Journal of Surgical Oncology 2008, 98:263-7. 10.1002/jso.21053, 18726889.
16. Chua TC, Morris DL, Esquivel J. Impact of the Peritoneal Surface Disease Severity Score on Survival in Patients with Colorectal Cancer Peritoneal Carcinomatosis Undergoing a Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology 2010, 17(5):1330-6. 10.1245/s10434-009-0866-x, 20033321.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.[see comment]. New England Journal of Medicine 2004, 350:2335-42. 10.1056/NEJMoa032691, 15175435.
18. Tol J, Koopman M, Cats A, et al. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. N Engl J Med 2009, 360:563-572. 10.1056/NEJMoa0808268, 19196673.
19. Van Cutsem E, Kohne C-H, Hitre E, et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. N Engl J Med 2009, 360:1408-1417. 10.1056/NEJMoa0805019, 19339720.